StockNews.AI

Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities

StockNews.AI • 3 days

ENABLECCHMCMAGCAP
High Materiality8/10

Information

CINCINNATI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”) a healthcare innova...

Original source

AI Summary

Sanofi has invested $30 million in Enable Injections, supporting the expansion of their enFuse® On-Body Delivery System's manufacturing capabilities. This partnership aids in delivering large-volume injectable therapies, particularly for multiple myeloma, and reflects Sanofi's commitment to enhancing subcutaneous treatments.

Trading Thesis

Sanofi’s investment in Enable could boost SNY’s oncology portfolio and growth prospects.

Market-Moving

  • Sanofi's $30 million investment reflects strong commitment to innovative therapies.
  • Enable's manufacturing expansion could lead to faster market entry for treatments.
  • Successful trials for Sarclisa may increase sales and market share.
  • Regulatory approvals enhance prospects for both Enable and Sanofi.
  • Strategic partnerships could drive long-term growth in oncology markets.

Key Facts

  • Enable's enFuse system is designed for subcutaneous administration of large volumes.
  • Sanofi's Sarclisa is used in ongoing clinical trials with the enFuse system.
  • Enable received FDA approval for enFuse technology in 2023.
  • A Manufacturing Center of Excellence is planned in Springdale, Ohio.
  • Enable has secured $215 million in Series C financing as of January 2022.

Companies Mentioned

  • Enable Injections (ENABLE): Focuses on innovative subcutaneous delivery solutions for biotechnology.
  • Sanofi (SNY): Key investor strengthening its position in the oncology market.
  • Cincinnati Children's Hospital Medical Center (CCHMC): Supportive investor in Enable Injections, reflecting confidence in healthcare innovation.
  • Magnetar Capital (MAGCAP): Led Enable's Series C financing, indicating strong investor interest.

Corporate Developments

The article highlights significant corporate development, showcasing Sanofi's strategic investment aimed at enhancing its product portfolio and manufacturing capabilities, which may positively influence its competitive position in oncology sectors.

FAQ

Why Bullish?

Sanofi's investment not only strengthens Enable's manufacturing capabilities but also enhances the potential for future collaborations, similar to past investments that significantly boosted market positions of biotech companies.

How important is it?

The investment from Sanofi is a significant indication of confidence in Enable's technology, likely eliciting positive investor sentiment towards SNY due to its strategic positioning in the growing oncology market.

Why Long Term?

Building manufacturing capacity and regulatory approvals will impact sales and market expansion over an extended period, as seen in previous strategic partnerships in biotech that led to growth post-investment.

Related Companies

ENABLECCHMCMAGCAP

Sanofi Invests $30 Million in Enable Injections to Enhance Manufacturing Capabilities

CINCINNATI, Jan. 6, 2026 (GLOBE NEWSWIRE) – Enable Injections, Inc. (“Enable”), a healthcare innovation company renowned for its enFuse® On-Body Delivery System (OBDS), has announced a strategic **$30 million investment** from Sanofi (**SNY**) aimed at accelerating its manufacturing capabilities. This investment is set to enhance Enable's supply chain and drive significant commercial growth.

Significance of the Investment

Michael D. Hooven, Chairman and CEO of Enable Injections, stated, “This investment from one of our key partners shows support for the enFuse platform and reflects our shared commitment to enhancing the convenience of large-volume subcutaneous injectable therapies for patients, particularly in oncology.” He emphasized that expanding manufacturing capabilities is essential to meet partner demands and offer innovative treatment options globally.

Boosting Manufacturing Capacity

This funding positions Enable to address the rising demand for the enFuse system, designed for the subcutaneous administration of large-volume medications with a simple button press. The system features a small, hidden, and retractable needle, making it user-friendly for patients.

  • Investment Amount: **$30 Million**
  • Investment Purpose: Accelerate manufacturing and supply chain capabilities
  • Focus: Convenience in large-volume subcutaneous injections

Collaboration with Sanofi

Enable’s enFuse hands-free on-body injector (OBI) was utilized in Sanofi's Sarclisa IRAKLIA phase 3 trial for newly diagnosed multiple myeloma (MM) and the IZALCO phase 2 trial for relapsed or refractory MM, both showcased at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2025. The OBI is designed to deliver the hyaluronidase-free formulation of Sarclisa subcutaneously and is currently under regulatory review.

Funding History and Future Prospects

This latest investment follows a history of robust funding for Enable Injections. In 2018, a Series B round led by Sanofi raised **$50 million**, further solidifying the partnership announced in 2019. Additionally, Enable closed a **$215 million Series C financing** in January 2022, spearheaded by Magnetar Capital, which included contributions from Sanofi and various new institutional investors.

In February 2024, Enable disclosed plans for a **90,000 square foot Manufacturing Center of Excellence** in Springdale, Ohio, alongside enhancements to its corporate headquarters in Evendale, Ohio. This initiative underscores Enable's commitment to large-scale manufacturing and commercialization.

About Enable Injections

Enable Injections, based in Cincinnati, is dedicated to transforming the patient treatment experience through its innovative enFuse® On-Body Delivery System. This ground-breaking wearable technology effectively delivers large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, aiming to enhance convenience and improve healthcare outcomes.

The company collaborates with several pharmaceutical partners to conduct clinical trials and develop joint commercialization strategies for therapies utilizing the enFuse system. The enFuse technology achieved its first combination product U.S. FDA approval in 2023 and has received device marketing authorizations from various international regulatory bodies.

For more information about Enable Injections and their innovative solutions, please visit www.enableinjections.com.

Media Contact

Aulani Capuchin
Real Chemistry
acapuchin@realchemistry.com
559-355-2673

Related News